Agilent Technologies Introduces New Exome Optimized for Clinical Research Sequencing
SureSelect Clinical Research Exome Provides Higher Coverage in Disease-Associated Regions
Agilent Technologies Inc. (NYSE: A) introduced the SureSelect Clinical Research Exome. The performance-optimized exome design was developed in collaboration with researchers from Emory University and the Children’s Hospital of Philadelphia.
SureSelect Human All Exon V5 was used as the core for the new design. Performance has been enhanced in disease-associated regions, providing 10 percent deeper coverage within these targets from only 4Gb of sequencing, while maintaining excellent coverage in other exome regions.
“Our goal was to create a comprehensive exome design that provides higher coverage in regions that are associated with human disease,” said Maduri Hedge, professor of Human Genetics at Emory University. “Agilent’s ability to enhance current targets and add custom content to the Human All Exon V5 provided an ideal solution to help us achieve this.”
The disease-relevant regions in the clinical research exome consist of gene targets commonly associated with, or known to cause, disease, including targets identified in OMIM, HGMD and NCBI’s ClinVar databases. Additional ancestry- and identity-informative content has also been included to facilitate sample tracking. Custom content can be added to the Clinical Research Exome using SureDesign, a free online design tool for SureSelect. The Clinical Research Exome targets approximately 54Mb of content and is optimized for coverage uniformity, enabling proportional performance improvement as sequencing allocation per library is increased. The SureSelect Clinical Research Exome can be paired with existing SureSelect kits to provide significantly reduced hybridization times-as little as 90 minutes-and provide sequencing-ready libraries in just one day.
“We are pleased to share this exceptional sequencing tool with the research community,” said Victor Fung, senior director of Marketing for Agilent’s Diagnostics and Genomics Solutions business. “It is unmatched in its ability to provide superior coverage, uniformity and efficiency in key regions, enabling up to two-and-a-half times greater sample throughput than any other exome available today.”
Agilent’s SureSelect portfolio is the industry’s leading target-enrichment solution. With reagents that address needs at every step of the target enrichment workflow, SureSelect enables a solution for researchers to quickly and easily analyze specific regions of the genome, transcriptome and methylome. As part of the complete solution, SureSelect is supported by SureDesign software that enables custom capability; Bravo automation platforms that enable reproducibility and high-throughput sample processing; 2100 Bioanalyzer and 2200 TapeStation for library QC; and SureCall software that enable streamlined analysis of genomic regions of interest from alignment to variant calling.
For more information about the SureSelect Clinical Research Exome, visit: www.agilent.com/genomics/clearanswers.
Dr. Hegde and Emory University are entitled to a portion of potential royalties received from Agilent for the licensed technology described above. The terms of the arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies.
About Agilent in Genomics
Agilent is a global leader in target enrichment solutions for next-generation sequencing and genomic microarrays. By synthesizing custom complex mixtures of long oligonucleotides, SureSelect and HaloPlex target enrichment solutions enable researchers to identify genomic regions of interest for focused, cost-effective variant profiling, with workflows that generate sequencing-ready libraries in just one day. Agilent’s unique manufacturing technology is the foundation for Agilent’s genomics portfolio, which includes SurePrint technology, for accurate genome-wide measurement of gene expression; arrayCGH, for combined copy number assessment with SNP information; and SureFISH, for highly sensitive and specific oligonucleotide fluorescent in-situ hybridization. Agilent also offers a microfluidic Bioanalyzer and TapeStation with complementary reagents and software for sample quantitation and quality assessment. For more information visit Agilent Genomics.About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
# # #
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.